Otonomy Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Otonomy Inc (OTIC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Otonomy Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 234M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-36.1% annualized vs trailing 12 months), vs decelerating (-96.5%) for its tracked peer group.
- Growth: Otonomy Inc generated -60.0% revenue growth year over year in Q3 2020, vs -82.1% for its tracked competitors combined.
- Profitability: Its -21,734.0% net margin compares with -810.1% for the peer group.
- Peer revenue share: Otonomy Inc accounted for 2.4% of combined revenue among its tracked peer group, up from 1.1% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
OTIC Sales vs. its Competitors, Q3 2020
Otonomy Inc reported revenue contraction of 60.00 % year on year in Q3 2020, above its competitors' combined revenue change of -82.10 %.
With a net margin of -21,734.00 %, Otonomy Inc reported lower profitability than its competitors (-810.14 %).
Otonomy Inc generated 2.38 % of the combined sales of its peer group, up from 1.08 % a year earlier.
Otonomy Inc vs. its Competitors, Q3 2020
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Otonomy Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Otonomy Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Otonomy Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -60.0% for Otonomy Inc. Otonomy Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Otonomy Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Otonomy Inc | - | - | - | Yes |
| Competitors combined (3) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
OTIC Stock Performance relative to its Competitors
OTIC Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Eton Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Zevra Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Otonomy Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Otonomy Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Otonomy Inc | 0.58 | 0.31 |
| Eton Pharmaceuticals Inc | 1,688.20 | 105.28 |
| Zevra Therapeutics Inc | 672.86 | 128.86 |
| Decibel Therapeutics Inc | 122.84 | - |
| SUBTOTAL | 2,484.48 | 234.45 |
Sources: Otonomy Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Otonomy Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Otonomy Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Altamira Therapeutics Ltd | Named by the company | 85% |
| Decibel Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Otonomy Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Otonomy Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Otonomy Inc | 1 | - | - |
| Eton Pharmaceuticals Inc | 1,688 | 2,392,705 | 288,364 |
| Zevra Therapeutics Inc | 673 | 2,112,377 | 949,246 |
| Decibel Therapeutics Inc | 123 | - | -1,584,800 |
| PEERS TOTAL | 2,484 | 1,614,717 | 49,655 |
Otonomy Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | 0.5x | 4.5x | -4.0x |
| Return on Equity | -137.86 % | industry aggregate | -155.10 % |
| Return on Invested Capital | -51.24 % | -2.85 % (avg) | -48.39 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Otonomy Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue Growth | 80.97 % | -39.72 % | -19.46 % | -54.50 % | - |
| Operating Margin | -7,394.90 % | -6,986.98 % | -7,467.83 % | -15,929.30 % | - |
| Return on Invested Capital | -31.86 % | -26.60 % | -31.94 % | -34.80 % | -31.87 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Otonomy Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 155.1 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-36.1% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-96.5% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Otonomy Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Otonomy Inc | 3.94 | 4.17 | 0.42 |
| Eton Pharmaceuticals Inc | 0.64 | 1.48 | 0.95 |
| Zevra Therapeutics Inc | 2.22 | 5.77 | 0.17 |
| Decibel Therapeutics Inc | 1.56 | 4.30 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Otonomy Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Otonomy Inc | Q3 2020 | - | - |
| Eton Pharmaceuticals Inc | Q2 2026 | +98.6 % | - |
| Zevra Therapeutics Inc | Q2 2026 | +53.3 % | -88.8 % |
| Decibel Therapeutics Inc | Q2 2023 | - | - |
| PEERS TOTAL | +72.4 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Otonomy Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Otonomy Inc | Q3 2020 | - | - |
| Eton Pharmaceuticals Inc | Q2 2026 | +73.9 % | - |
| Zevra Therapeutics Inc | Q2 2026 | -87.7 % | +1.9 % |
| Decibel Therapeutics Inc | Q2 2023 | - | - |
Otonomy Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Otonomy Inc | - | - | - |
| Eton Pharmaceuticals Inc | 12.37% | 21.31% | 40.13% |
| Zevra Therapeutics Inc | 20.39% | 22.90% | 32.56% |
| Decibel Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Otonomy Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Otonomy Inc | - | 1.85 |
| Eton Pharmaceuticals Inc | 132.03 | 16.04 |
| Zevra Therapeutics Inc | 11.67 | 5.22 |
| Decibel Therapeutics Inc | - | - |
| PEERS AVERAGE | - | 10.60 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.